Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02559778 · ClinicalTrials.gov registry record · Phase 2
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
A Phase 2 study of Neuroblastoma, sponsored by Giselle Sholler.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT02559778: Recruiting Phase 2 study of Neuroblastoma, sponsored by Giselle Sholler.
NCT02559778 is a Phase 2 study of Neuroblastoma that is actively recruiting participants, run by Giselle Sholler. The registered enrollment target is 500 participants, above the 234-participant average among 94 other Neuroblastoma trials with a reported enrollment target (114% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02559778, a Phase 2 study of Neuroblastoma, is actively recruiting participants, sponsored by Giselle Sholler.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Primary Outcome
To measure the response of treatments chosen based on: • Event free survival (EFS)
Conditions Studied
Interventions
- DRUG DFMO
- DRUG Ceritinib
- DRUG dasatinib
- DRUG sorafenib
- DRUG vorinostat
Study Locations (20)
Florida
- Nicklaus Children's Miami - Miami
- Arnold Palmer Hospital for Children - Orlando
- St. Joseph's Children's Hospital - Tampa
California
- UCSF Benioff Children's Hospital Oakland - Oakland
- Rady Children's Hospital - San Diego
Missouri
- Children's Mercy Hospitals and Clinics - Kansas City
- Cardinal Glennon Children's Medical Center - St Louis
Alabama
- University of Alabama/Children's of Alabama - Birmingham
Arkansas
- Arkansas Children's Hospital - Little Rock
Connecticut
- Connecticut Children's Hospital - Hartford
Georgia
- Augusta University Health - Augusta
Hawaii
- Kapiolani Medical Center for Women and Children - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2015-09 |
| Est. Completion | 2035-09 |
| Phase | Phase 2 |
What NCT02559778 shows while recruiting
NCT02559778 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 234-participant average among 94 other Neuroblastoma trials with a reported enrollment target (114% higher).
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 5 interventions - of which DFMO is the first listed.
NCT02559778 names 20 study sites across 16 states, led by Florida, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT02559778 about?
NCT02559778 is a clinical study titled "Pediatric Precision Laboratory Advanced Neuroblastoma Therapy". A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with ...
What is the current status of trial NCT02559778?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2015-09. Estimated completion is 2035-09.
What conditions does trial NCT02559778 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT02559778?
The interventions under investigation include: DFMO (DRUG), Ceritinib (DRUG), dasatinib (DRUG), sorafenib (DRUG), vorinostat (DRUG).
Who is sponsoring clinical trial NCT02559778?
This trial is sponsored by Giselle Sholler, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02559778 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02559778's enrollment target sits among peer trials
500 9th of 94 higher than 86 of 94 other Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
RECRUITING · Phase 2
-
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 2
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
RECRUITING · Phase 2
-
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
RECRUITING · Phase 2
-
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia